INTERNATIONAL PATENT: MEIJI SEIKA PHARMA CO., LTD., ＭＥＩＪＩ　ＳＥＩＫＡファルマ株式会社, UNIVERSITY OF MIYAZAKI, 国立大学法人　宮崎大学 FILES APPLICATION FOR "BISPECIFIC ANTIBODY THAT IS EFFECTIVE FOR T-CELL TUMOR PATIENTS WITH T-CELL DYSFUNCTION"

Posted On: 2025-10-28

GENEVA, Oct. 28 -- MEIJI SEIKA PHARMA CO., LTD. (4-16, Kyobashi 2-chome, Chuo-ku, Tokyo1048002), Ｍｅｉｊｉ　Ｓｅｉｋａファルマ株式会社 (東京都中央区京橋２丁目４番１６号), UNIVERSITY OF MIYAZAKI (1-1, Gakuen Kibana-dai Nishi, Miyazaki-shi, Miyazaki8892192), 国立大学法人　宮崎大学 (宮崎県宮崎市学園木花台西１丁目１番地) filed a patent application (PCT/JP2025/014934)...

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

INTERNATIONAL PATENT: MEIJI SEIKA PHARMA CO., LTD., ＭＥＩＪＩ　ＳＥＩＫＡファルマ株式会社, UNIVERSITY OF MIYAZAKI, 国立大学法人　宮崎大学 FILES APPLICATION FOR "BISPECIFIC ANTIBODY THAT IS EFFECTIVE FOR T-CELL TUMOR PATIENTS WITH T-CELL DYSFUNCTION"

Exclusive

Category

Source

Publication

Location

INTERNATIONAL PATENT: MEIJI SEIKA PHARMA CO., LTD., ＭＥＩＪＩ ＳＥＩＫＡファルマ株式会社, UNIVERSITY OF MIYAZAKI, 国立大学法人 宮崎大学 FILES APPLICATION FOR "BISPECIFIC ANTIBODY THAT IS EFFECTIVE FOR T-CELL TUMOR PATIENTS WITH T-CELL DYSFUNCTION"

INTERNATIONAL PATENT: MEIJI SEIKA PHARMA CO., LTD., ＭＥＩＪＩ　ＳＥＩＫＡファルマ株式会社, UNIVERSITY OF MIYAZAKI, 国立大学法人　宮崎大学 FILES APPLICATION FOR "BISPECIFIC ANTIBODY THAT IS EFFECTIVE FOR T-CELL TUMOR PATIENTS WITH T-CELL DYSFUNCTION"